Case for Support 2024
Breast Cancer Network Australia
Voice
BCNA continues its sector-leading advocacy to achieve better breast cancer outcomes and support
Advocacy has always been at the heart of what we do at BCNA. Our voice has influenced local and national solutions, as well as global policy reform. It has led to fundamental changes in the delivery of breast cancer care. We are the go-to consumer voice on breast cancer for policy makers, researchers and practitioners. We are recognised nationally and internationally as an organisation that improves breast cancer outcomes and equity through advocacy that harnesses the diverse voices of those with a lived experience. Through our voice, networks, and the stories of those we represent, we work to ensure that – no matter who you are or where you live – people affected by breast cancer have access to the very best care. Our landmark campaigns for Herceptin (trastuzumab) in 2001 and 2006 set a powerful precedent. Building on this legacy, we've secured government subsidy for more crucial breast cancer drugs that have drastically reduced costs of treatments for some from $10,000 to $15,000 every three months to a more affordable level, improving access and extending lives. Responding to the needs identified by our network, we are focussed on reducing the financial impact of a breast cancer diagnosis, improving access to live- saving and life-extending drugs and better cancer care, enhancing quality of life and improving outcomes through increased prevention and early detection.
In 2025, we are redoubling our commitment to positively influence cancer policy, practice, and treatment. Our expert policy and advocacy team will engage across our national consumer network and key stakeholders, ensuring our planned advocacy actions remain relevant, targeted, and bipartisan. This approach allows us to stay focused on the issues that matter most to people impacted by breast cancer, while maintaining independence from government, the for-profit pharmaceutical industry, and the broader biomedical sector.
Vicki Durston, Director Policy, Advocacy and Support Services, BCNA at the press conference announcing the listing of Enhertu for the treatment of a new sub- type of metastatic breast cancer, HER2-Low, on the Pharmaceutical Benefits Scheme (PBS). September, 2024
When BCNA speaks, people listen. Patricia Edgar AO Founding Chair BCNA
8
9
Made with FlippingBook - professional solution for displaying marketing and sales documents online